我国幽门螺杆菌感染患者原发耐药情况以及不同根除方案对其疗效前瞻性多中心研究.ppt

我囝幽门螺杆首臧樂意者原发耐翥情况以及 不同根除方素对其影响的 前瞻性箩中心研宽  A Comparative Study of Sequential Therapy and Standard Triple Therapy for Helicobacter py lor i Infection: A Randomized Multicenter trial  Introduction ■2014年4月 Am j gastroenterol发表了北京大学第三医院 消化科周丽雅教授牵头的一项国内5家中心共同完成的临 床试验“序贯方案和标准三联方案在我国幽门螺杆菌感 染初治患者中的多中心、随机对照研究”( Zhou l, Zhang J, Chen M,et a1. a comparative study of sequential therapy and standard triple therapy for helicobacter pylori infection: a randomized multicenter trial. Am J] Gastroenterol, 2014, 109: 535-541), 统严格地比较了序贯方案和标准三联方案根除幽门螺杆 菌(Hp)感染的疗效、安全性、依从性等问题,并深人探 讨了抗菌药物耐药对序贯方案疗效的影响  Background a Helicobacter pylori( H. pylori)infection is an important causal factor in a wide range of upper gastrointestinal diseases, including chronic gastritis, peptic ulcer disease, and gastric cancer. As such, it is a major contributor that affects public health on a worldwide basis especially in developing countries  Background Traditionally, standard triple therapy(stt comprising a proton pump inhibitor(PPI) combined with two antibiotics(clarithromycin and amoxicillin or metronidazole) is the firstline option for empiriC H pylori eradication. However, the effectiveness of STT has declined to unacceptable levels in many regions of the world, mainly owing to antibiotic resistance. Consequently, it is no longer a suitable first-line treatment approach and there is a clear need for new regimens with good efficacy and safety in order to effectively manage this widespread form of infection